Tanios S. Bekaii-Saab, MD, FACP

Articles

Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW Study

January 31st 2024

In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for metastatic colorectal cancer with high microsatellite instability and deficient mismatch repair.

Biomarker Testing and Next-Generation Sequencing Inform Modern Treatment Strategies for mCRC

August 3rd 2022

Dr. Bekaii-Saab shares the approach his practice takes to essential biomarker testing and next-generation sequencing in order to improve patient outcomes.

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

May 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Dr. Bekaii-Saab on the Need for Umbrella Trials in Biliary Tract Cancer

April 17th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the need for umbrella trials in biliary tract cancer.

Dr. Bekaii-Saab on the Impact of COVID-19 on Telemedicine

April 10th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC

October 23rd 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC

October 5th 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab on the APACT Trial in Pancreatic Cancer

September 30th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the implications of the randomized phase III APACT trial evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel as adjuvant therapy in patients with pancreatic cancer.